Earnings Call · Q2 FY2021·2021-07-28

Q2 21EPS +54.55%·Rev n/aQ1 21EPS +7.14%·Rev n/aQ4 20EPS +7.14%·Rev n/aQ3 20EPS +10.00%·Rev n/a⚠ consensus missing

Vanda Pharmaceuticals Inc. VNDA

Kevin Moran — Chief Financial Officer

Mihael Polymeropoulos — Chief Executive Officer

−8.5%1d on move date−8.9% vs SPY3d−13.4%5d−18.4%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more VNDA calls or request research access.

More VNDA calls Browse calls Request research access